News

The approval of infliximab-dyyb as a maintenance therapy following IV infliximab for patients with moderately to severely active ulcerative colitis and Crohn disease was announced on October 22, 2023.

Thomas F. Imperiale, MD, discusses the pivotal findings showing improvements to the prior iteration of Cologuard, as well as bettered sensitivity and specificty relative to fecal immunochemical tests.

The first-of-its-kind Aurora EV-ICD system offers a single-device, single procedure with a lead placed outside of the heart and veins.

Data presented at ACG 2023 shows a significantly increased risk of infection and hospitalization due to RSV in patients with IBD. An investigator discusses implications during an era of increased vaccine options.

An analysis of data from nearly 500 patients provides insight into the contributions of anemia to reduced exercise tolerance observed in patients with heart failure with preserved ejection fraction.

Presented at United European Gastroenterology Week 2023, results of the retrospective study showed ferric maltol was safe for us in pregnant patients with IBD and iron deficiency anemia.

Dr. Eichenfield used this interview segment to respond to the FDA’s recent decision not to approve dupilumab for chronic spontaneous urticaria.

New phase 1b data supports further investigation into Adiso Therapeutic's prospective treatment.

Post-hoc analysis clarifies efficacy of upadacitinib for patients with moderately to severely active Crohn's disease with a CDAI of 220 or more.

Presented in an abstract at ACG 2023, filgotinib missed both co-primary endpoints at week 10 but was efficacious at week 52 in the maintenance cohorts.

Dr. Eichenfield spoke in this interview segment on the tips shared in his presentation at the Fall Clinical Dermatology conference in Las Vegas.

Tildrakizumab significantly improved work productivity and reduced work activity impairment in patients with moderate to severe plaque psoriasis, highlighting this treatment's quality of life benefits.

Secukinumab treatment resulted in greater improvements compared with placebo at week 12, with responses increasing through week 52.

Results from the POETYK PSO-1 trial showed significantly greater improvements in patients receiving deucravacitinib compared with placebo or apremilast.

In this interview, Dr. Eichenfield shared his views on this week’s approval by the FDA of IDP-126 for patients 12 and older with acne.

This interview segment explored the major takeaways from Dr. Chovatiya’s presentation on Type 2 Inflammation in eczema, prurigo nodularis, and chronic spontaneous urticaria.

In this interview segment, Dr. Chovatiya discussed the challenges of diagnosing Type 2 inflammation in several different dermatologic diseases.

In this talk presented at the Fall Clinical Dermatology conference, Dr. James Del Rosso and Dr. Alexandra Golant debate the benefits of JAK inhibitors and monoclonal antibodies.

Linda Stein Gold, MD, explains how the safety considerations of nonsteroidal topicals must be weighed against their significant value in the treatment arsenal.

Linda Stein Gold, MD, discusses the notable transition in topical therapies for both psoriasis and atopic dermatitis, with the introduction of effective FDA-approved nonsteroidal treatments.

In this interview, Dr. Chovatiya touched on several important updates and recent developments in the JAK inhibitor space for dermatologists.

Designed to treat the acne's inflammation, bacteria and follicular hyperkeratinization, IDP-126 has shown significant efficacy compared to standard-care options already on the market.

In this interview segment, Dr. Nestor speaks on some of his biggest takeaways from his talk ‘What’s Coming Up Next?’ given at the Fall Clinical Dermatology conference.

April Armstrong, MD, MPH, explains how early detection of psoriatic arthritis and psoriasis is critical to prevent irreversible joint damage and improve patient outcomes.

April Armstrong, MD, MPH, explains the effectiveness of interleukin (IL)-17 and IL-23 inhibitors in treating moderate to severe plaque psoriasis and psoriatic arthritis.

Individuals in racial and ethnic minority groups and those with lower socioeconomic status were less likely to consent to participate in ophthalmic clinical studies.

The latest indication for the dual inflammatory pathway-targeting biologic expands dupilumab's clinical availability to third chronic skin disease.

The expanded Indication now includes children of all ages with achondroplasia, the most common form of skeletal dysplasia leading to disproportionate short stature.